TapewireFind a company

person · Reporting owner

SHAPIRO LEE

Disclosed activity across 5 companies

Tapewire entity
84281
SEC CIK
0001213350

Export transaction history ↓

Reported relationships

Latest disclosed role at each company.

CompanyLast reported asReport datePublished
CLOVER HEALTH INVESTMENTS, CORP. /DECLOV · Entity 4419DirectorJanuary 06, 2025January 08, 2025
Senior Connect Acquisition Corp. ISNRH · Entity 112401DirectorDecember 10, 2020December 10, 2020
TIVITY HEALTH, INC.TVTY · Entity 125776DirectorFebruary 28, 2020February 28, 2020

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

CLOVER HEALTH INVESTMENTS, CORP. /DE

Report date January 06, 2025 · Filed January 08, 2025

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Class A Common StockSEC Table I · non-derivativeDirect598,622 Reported balance After 2025-01-06 transaction · row 1
1 source row

Row 1 · 2025-01-06 · Grant · Acquired 60,975 · Balance 598,622

F1: Represents shares of Class A common stock underlying a time-based restricted stock unit award (RSUs). The RSUs will vest in full on the first anniversary of January 6, 2025, subject to the Reporting Person's continued service as a director through such vesting date.

Filing footnotes · ownership attribution and instrument terms

F1: Represents shares of Class A common stock underlying a time-based restricted stock unit award (RSUs). The RSUs will vest in full on the first anniversary of January 6, 2025, subject to the Reporting Person's continued service as a director through such vesting date.

Senior Connect Acquisition Corp. I

Report date December 10, 2020 · Filed December 10, 2020

This filing explicitly reported no securities owned.

TIVITY HEALTH, INC.

Report date February 28, 2020 · Filed February 28, 2020

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Common StockSEC Table I · non-derivativeDirect40,304 Reported balance After 2020-02-28 transaction · row 1
1 source row

Row 1 · 2020-02-28 · Purchase · Acquired 4,065 · Balance 40,304

Past disclosures · reporting ended (2)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

Livongo Health, Inc.

Report date September 11, 2020 · Filed October 30, 2020

Section 16 reporting ended · disclosed 2020-10-30. Current position is not established by this disclosure.

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Common StockSEC Table I · non-derivativeIndirectSee footnote12,080 Reported balance After 2020-09-11 transaction · row 1 Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source row

Row 1 · 2020-09-11 · Other · Acquired 12,080 · Balance 12,080

F1: Represents the receipt of shares pursuant to a pro rata in-kind distribution by 7wire Ventures Wanxiang Strategic Fund I, LP.

F2: The shares are held of record by 7wire Management I, LLC. The reporting person serves as a Manager of 7wire Management, LLC, or 7wire Management, the Manager of 7wire Management I, LLC. The reporting person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of the securities for purposes of Section 16 or for any other purpose.

Common StockSEC Table I · non-derivativeIndirectSee footnote0 Reported balance After 2020-10-29 transaction · row 3 Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source row

Row 3 · 2020-10-29 · Other · Disposed 1,185,097 · Balance 0

F3: Represents a pro rata in-kind distribution by 7wire Ventures, LLC - Series EosHealth without consideration to its partners.

F4: The shares were held of record by 7wire Ventures LLC - Series EosHealth. The reporting person serves as a Manager of 7wire Management, the Manager of 7wire Ventures LLC - Series EosHealth. The reporting person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of the securities for purposes of Section 16 or for any other purpose.

Common StockSEC Table I · non-derivativeIndirectSee footnote0 Reported balance After 2020-10-29 transaction · row 4 Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source row

Row 4 · 2020-10-29 · Other · Disposed 109,748 · Balance 0

F5: Represents a pro rata in-kind distribution by 7wire Ventures LLC - Series Livongo C without consideration to its partners.

F6: The shares were held of record by 7wire Ventures LLC - Series Livongo C. The reporting person serves as a Manager of 7wire Management, the Manager of 7wire Ventures LLC - Series Livongo C. The reporting person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of the securities for purposes of Section 16 or for any other purpose.

Common StockSEC Table I · non-derivativeIndirectSee footnote0 Reported balance After 2020-10-29 transaction · row 5 Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source row

Row 5 · 2020-10-29 · Other · Disposed 176,361 · Balance 0

F7: Represents a pro rata in-kind distribution by 7wire Ventures LLC - Series Livongo D without consideration to its partners.

F8: The shares were held of record by 7wire Ventures LLC - Series Livongo D. The reporting person serves as a Manager of 7wire Management, the Manager of 7wire Ventures LLC - Series Livongo D. The reporting person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of the securities for purposes of Section 16 or for any other purpose.

Common StockSEC Table I · non-derivativeIndirectSee footnote0 Reported balance After 2020-10-29 transaction · row 6 Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source row

Row 6 · 2020-10-29 · Other · Disposed 195,277 · Balance 0

F9: Represents a pro rata in-kind distribution by 7wire Ventures LLC - Series Livongo E without consideration to its partners.

F10: The shares were held of record by 7wire Ventures LLC - Series Livongo E. The reporting person serves as a Manager of 7wire Management, the Manager of 7wire Ventures LLC - Series Livongo E. The reporting person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of the securities for purposes of Section 16 or for any other purpose.

Common StockSEC Table I · non-derivativeIndirectSee footnote35,887 Reported balance After 2020-10-30 transaction · row 8 Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source row

Row 8 · 2020-10-30 · Other · Disposed 940,788 · Balance 35,887

F13: Represents a pro rata in-kind distribution by 7wire Ventures Fund, L.P. without consideration to its partners.

F14: The shares are held of record by 7wire Ventures Fund, L.P. The reporting person serves as a Manager of 7wire Management, the Manager of 7wire Ventures Fund, L.P. The reporting person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of the securities for purposes of Section 16 or for any other purpose.

Common StockSEC Table I · non-derivativeIndirectSee footnote185,121 Reported balance After 2020-10-30 transaction · row 10 Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source row

Row 10 · 2020-10-30 · Other · Acquired 173,041 · Balance 185,121

F16: Represents the receipt of shares pursuant to pro rata in-kind distributions by 7wire Ventures Fund L.P. and 7wire Ventures Wanxiang Strategic Fund I, LP.

F2: The shares are held of record by 7wire Management I, LLC. The reporting person serves as a Manager of 7wire Management, LLC, or 7wire Management, the Manager of 7wire Management I, LLC. The reporting person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of the securities for purposes of Section 16 or for any other purpose.

Common StockSEC Table I · non-derivativeIndirectSee footnote0 Reported balance After 2020-10-30 transaction · row 13 Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source row

Row 13 · 2020-10-30 · Disposition to issuer · Disposed 35,887 · Balance 0

F19: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of August 5, 2020, by and among the Issuer, Teladoc Health, Inc. ("Teladoc"), and Tempranillo Merger Sub, Inc., a wholly owned subsidiary of Teladoc, each share of the Issuer's common stock was converted into the right to receive 0.5920 of a share of Teladoc common stock and $4.24 in cash, without interest, together with cash in lieu of fractional shares (if any).

F14: The shares are held of record by 7wire Ventures Fund, L.P. The reporting person serves as a Manager of 7wire Management, the Manager of 7wire Ventures Fund, L.P. The reporting person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of the securities for purposes of Section 16 or for any other purpose.

Common StockSEC Table I · non-derivativeIndirectSee footnote0 Reported balance After 2020-10-30 transaction · row 14 Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source row

Row 14 · 2020-10-30 · Disposition to issuer · Disposed 185,121 · Balance 0

F19: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of August 5, 2020, by and among the Issuer, Teladoc Health, Inc. ("Teladoc"), and Tempranillo Merger Sub, Inc., a wholly owned subsidiary of Teladoc, each share of the Issuer's common stock was converted into the right to receive 0.5920 of a share of Teladoc common stock and $4.24 in cash, without interest, together with cash in lieu of fractional shares (if any).

F2: The shares are held of record by 7wire Management I, LLC. The reporting person serves as a Manager of 7wire Management, LLC, or 7wire Management, the Manager of 7wire Management I, LLC. The reporting person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of the securities for purposes of Section 16 or for any other purpose.

Common StockSEC Table I · non-derivativeDirect1,693,023 Reported balance After 2020-10-16 transaction · row 2 Account or security details depend on footnotes; rows are not merged.
1 source row

Row 2 · 2020-10-16 · Gift · Disposed 135,000 · Balance 1,693,023

Common StockSEC Table I · non-derivativeDirect1,718,701 Reported balance After 2020-10-29 transaction · row 7 Account or security details depend on footnotes; rows are not merged.
1 source row

Row 7 · 2020-10-29 · Other · Acquired 25,468 · Balance 1,718,701

F11: Represents the receipt of shares pursuant to pro rata in-kind distributions by 7wire Ventures LLC - Series Livongo D and 7wire Ventures LLC - Series Livongo E.

F12: Includes 210 shares acquired under the Livongo Health, Inc. 2019 Employee Stock Purchase Plan on October 28, 2020.

Common StockSEC Table I · non-derivativeDirect1,745,807 Reported balance After 2020-10-30 transaction · row 9 Account or security details depend on footnotes; rows are not merged.
1 source row

Row 9 · 2020-10-30 · Other · Acquired 27,106 · Balance 1,745,807

F15: Represents the receipt of shares pursuant to a pro rata in-kind distribution by 7wire Ventures Fund L.P.

Common StockSEC Table I · non-derivativeDirect1,743,319 Reported balance After 2020-10-30 transaction · row 11 Account or security details depend on footnotes; rows are not merged.
1 source row

Row 11 · 2020-10-30 · Disposition to issuer · Disposed 2,488 · Balance 1,743,319

F17: Represents restricted stock units ("RSUs") voluntarily forfeited to the Issuer.

Common StockSEC Table I · non-derivativeDirect0 Reported balance After 2020-10-30 transaction · row 12 Account or security details depend on footnotes; rows are not merged.
1 source row

Row 12 · 2020-10-30 · Disposition to issuer · Disposed 1,743,319 · Balance 0

F18: Includes 763,507 RSUs.

F19: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of August 5, 2020, by and among the Issuer, Teladoc Health, Inc. ("Teladoc"), and Tempranillo Merger Sub, Inc., a wholly owned subsidiary of Teladoc, each share of the Issuer's common stock was converted into the right to receive 0.5920 of a share of Teladoc common stock and $4.24 in cash, without interest, together with cash in lieu of fractional shares (if any).

F20: Pursuant to the Merger Agreement, each outstanding RSU award of the Issuer was converted into a number of RSUs with respect to a number of shares of Teladoc common stock equal to the product of (i) the number of shares of the Issuer's common stock subject to such RSU award immediately prior to the effective time of the merger and (ii) the Equity Award Adjustment Ratio (as defined below) (rounded down to the nearest whole share of Teladoc common stock on an award-by-award basis), subject to the same terms and conditions as were applicable to such Issuer RSU immediately prior to the effective time of the merger (including applicable vesting conditions).

F21: The "Equity Award Adjustment Ratio" means the quotient determined by dividing (i) the volume weighted average closing price of the Issuer's common stock on the four trading days ending on October 29, 2020 by (ii) the volume weighted average closing price of Teladoc common stock on the four trading days beginning on October 29, 2020.

Filing footnotes · ownership attribution and instrument terms

F1: Represents the receipt of shares pursuant to a pro rata in-kind distribution by 7wire Ventures Wanxiang Strategic Fund I, LP.

F2: The shares are held of record by 7wire Management I, LLC. The reporting person serves as a Manager of 7wire Management, LLC, or 7wire Management, the Manager of 7wire Management I, LLC. The reporting person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of the securities for purposes of Section 16 or for any other purpose.

F3: Represents a pro rata in-kind distribution by 7wire Ventures, LLC - Series EosHealth without consideration to its partners.

F4: The shares were held of record by 7wire Ventures LLC - Series EosHealth. The reporting person serves as a Manager of 7wire Management, the Manager of 7wire Ventures LLC - Series EosHealth. The reporting person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of the securities for purposes of Section 16 or for any other purpose.

F5: Represents a pro rata in-kind distribution by 7wire Ventures LLC - Series Livongo C without consideration to its partners.

F6: The shares were held of record by 7wire Ventures LLC - Series Livongo C. The reporting person serves as a Manager of 7wire Management, the Manager of 7wire Ventures LLC - Series Livongo C. The reporting person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of the securities for purposes of Section 16 or for any other purpose.

F7: Represents a pro rata in-kind distribution by 7wire Ventures LLC - Series Livongo D without consideration to its partners.

F8: The shares were held of record by 7wire Ventures LLC - Series Livongo D. The reporting person serves as a Manager of 7wire Management, the Manager of 7wire Ventures LLC - Series Livongo D. The reporting person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of the securities for purposes of Section 16 or for any other purpose.

F9: Represents a pro rata in-kind distribution by 7wire Ventures LLC - Series Livongo E without consideration to its partners.

F10: The shares were held of record by 7wire Ventures LLC - Series Livongo E. The reporting person serves as a Manager of 7wire Management, the Manager of 7wire Ventures LLC - Series Livongo E. The reporting person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of the securities for purposes of Section 16 or for any other purpose.

F11: Represents the receipt of shares pursuant to pro rata in-kind distributions by 7wire Ventures LLC - Series Livongo D and 7wire Ventures LLC - Series Livongo E.

F12: Includes 210 shares acquired under the Livongo Health, Inc. 2019 Employee Stock Purchase Plan on October 28, 2020.

F13: Represents a pro rata in-kind distribution by 7wire Ventures Fund, L.P. without consideration to its partners.

F14: The shares are held of record by 7wire Ventures Fund, L.P. The reporting person serves as a Manager of 7wire Management, the Manager of 7wire Ventures Fund, L.P. The reporting person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of the securities for purposes of Section 16 or for any other purpose.

F15: Represents the receipt of shares pursuant to a pro rata in-kind distribution by 7wire Ventures Fund L.P.

F16: Represents the receipt of shares pursuant to pro rata in-kind distributions by 7wire Ventures Fund L.P. and 7wire Ventures Wanxiang Strategic Fund I, LP.

F17: Represents restricted stock units ("RSUs") voluntarily forfeited to the Issuer.

F18: Includes 763,507 RSUs.

F19: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of August 5, 2020, by and among the Issuer, Teladoc Health, Inc. ("Teladoc"), and Tempranillo Merger Sub, Inc., a wholly owned subsidiary of Teladoc, each share of the Issuer's common stock was converted into the right to receive 0.5920 of a share of Teladoc common stock and $4.24 in cash, without interest, together with cash in lieu of fractional shares (if any).

F20: Pursuant to the Merger Agreement, each outstanding RSU award of the Issuer was converted into a number of RSUs with respect to a number of shares of Teladoc common stock equal to the product of (i) the number of shares of the Issuer's common stock subject to such RSU award immediately prior to the effective time of the merger and (ii) the Equity Award Adjustment Ratio (as defined below) (rounded down to the nearest whole share of Teladoc common stock on an award-by-award basis), subject to the same terms and conditions as were applicable to such Issuer RSU immediately prior to the effective time of the merger (including applicable vesting conditions).

F21: The "Equity Award Adjustment Ratio" means the quotient determined by dividing (i) the volume weighted average closing price of the Issuer's common stock on the four trading days ending on October 29, 2020 by (ii) the volume weighted average closing price of Teladoc common stock on the four trading days beginning on October 29, 2020.

Medidata Solutions, Inc.

Report date October 28, 2019 · Filed October 28, 2019

Section 16 reporting ended · disclosed 2019-10-28. Current position is not established by this disclosure.

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Common StockSEC Table I · non-derivativeDirect0 Reported balance After 2019-10-28 transaction · row 1
1 source row

Row 1 · 2019-10-28 · Disposition to issuer · Disposed 28,827 · Balance 0

F1: On October 28, 2019, pursuant to the Agreement and Plan of Merger, dated as of June 11, 2019, by and among Dassault Systemes SE ("DS"), Dassault Systemes Americas Corp., a Delaware corporation ("Parent"), 3DS Acquisition 6 Corp., a Delaware corporation and a wholly-owned subsidiary of Parent ("Merger Sub"), and Medidata Solutions, Inc., a Delaware corporation (the "Issuer"), Merger Sub merged with and into the Issuer, with the Issuer surviving as a wholly-owned subsidiary of Parent and an indirect wholly-owned subsidiary of DS (the "Merger").

F2: Disposed of pursuant to the Merger Agreement and by virtue of the Merger, in which each share of Medidata common stock, par value $0.01 per share ("Issuer Common Stock"), issued and outstanding immediately prior to the completion of the Merger (other than restricted share awards held by continuing employees) was converted into the right to receive $92.25 in cash and without interest (the "Merger Consideration").

Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $11.50 · Expires 2021-05-31Direct0 Reported balance After 2019-10-28 transaction · row 2 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 2 · 2019-10-28 · Disposition to issuer · Disposed 4,494 · Balance 0

F3: Pursuant to the Merger Agreement and by virtue of the Merger, each option to purchase Issuer Common Stock will be cancelled and converted into the right to receive an amount in cash (without interest and subject to deduction for any required withholding tax) equal to the product of (1) the total number of shares of Issuer Common Stock then covered by such option multiplied by (2) the excess, if any, of $92.25 per share over the exercise price per share under such option.

F4: These options are fully vested and exercisable.

Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $13.98 · Expires 2022-05-16Direct0 Reported balance After 2019-10-28 transaction · row 3 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 3 · 2019-10-28 · Disposition to issuer · Disposed 5,214 · Balance 0

F3: Pursuant to the Merger Agreement and by virtue of the Merger, each option to purchase Issuer Common Stock will be cancelled and converted into the right to receive an amount in cash (without interest and subject to deduction for any required withholding tax) equal to the product of (1) the total number of shares of Issuer Common Stock then covered by such option multiplied by (2) the excess, if any, of $92.25 per share over the exercise price per share under such option.

F4: These options are fully vested and exercisable.

Filing footnotes · ownership attribution and instrument terms

F1: On October 28, 2019, pursuant to the Agreement and Plan of Merger, dated as of June 11, 2019, by and among Dassault Systemes SE ("DS"), Dassault Systemes Americas Corp., a Delaware corporation ("Parent"), 3DS Acquisition 6 Corp., a Delaware corporation and a wholly-owned subsidiary of Parent ("Merger Sub"), and Medidata Solutions, Inc., a Delaware corporation (the "Issuer"), Merger Sub merged with and into the Issuer, with the Issuer surviving as a wholly-owned subsidiary of Parent and an indirect wholly-owned subsidiary of DS (the "Merger").

F2: Disposed of pursuant to the Merger Agreement and by virtue of the Merger, in which each share of Medidata common stock, par value $0.01 per share ("Issuer Common Stock"), issued and outstanding immediately prior to the completion of the Merger (other than restricted share awards held by continuing employees) was converted into the right to receive $92.25 in cash and without interest (the "Merger Consideration").

F3: Pursuant to the Merger Agreement and by virtue of the Merger, each option to purchase Issuer Common Stock will be cancelled and converted into the right to receive an amount in cash (without interest and subject to deduction for any required withholding tax) equal to the product of (1) the total number of shares of Issuer Common Stock then covered by such option multiplied by (2) the excess, if any, of $92.25 per share over the exercise price per share under such option.

F4: These options are fully vested and exercisable.

Transaction history

JSON API
Reset

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction dateCompanyActivity / securityShares / unitsReported priceReported valueDetails
April 09, 2020 Filed Apr 13, 2020 19:22 UTC Livongo Health, Inc. LVGO · Entity 145566 OtherCommon Stock 93,790 $0.00 $0.00
Disclosure

SEC source: 0000899243-20-010679 · doc4.xml · nonDerivative · entry 4

SHAPIRO LEE · CIK 0001213350 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 191,341

F3 · kind: Represents a pro rata in-kind distribution by 7wire Ventures LLC - Series Livongo C without consideration to its partners (including 7wire LP).

F4 · ownership.nature: The shares are held of record by 7wire Ventures LLC - Series Livongo C. The reporting person serves as a Manager of 7wire Management, the Manager of 7wire Ventures LLC - Series Livongo C. The reporting person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of the securities for purposes of Section 16 or for any other purpose.

Read SEC document
April 09, 2020 Filed Apr 13, 2020 19:22 UTC Livongo Health, Inc. LVGO · Entity 145566 OtherCommon Stock 1,307,682 $0.00 $0.00
Disclosure

SEC source: 0000899243-20-010679 · doc4.xml · nonDerivative · entry 3

SHAPIRO LEE · CIK 0001213350 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 2,066,305

F1 · kind: Represents a pro rata in-kind distribution by 7wire Ventures, LLC - Series EosHealth without consideration to its partners (including 7wire Ventures Fund, L.P., or 7wire LP).

F2 · ownership.nature: The shares are held of record by 7wire Ventures LLC-Series EosHealth. The reporting person serves as a Manager of 7wire Management, LLC, or 7wire Management, the Manager of 7wire Ventures LLC-Series EosHealth. The reporting person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of the securities for purposes of Section 16 or for any other purpose.

Read SEC document
March 18, 2020 Filed Mar 19, 2020 18:00 UTC Livongo Health, Inc. LVGO · Entity 145566 Tax withholdingCommon Stock 1,322 $23.00 $30,406.00
Disclosure

SEC source: 0001209191-20-020322 · doc4.xml · nonDerivative · entry 1

SHAPIRO LEE · CIK 0001213350 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,852,900

F1 · kind: The reported shares were withheld to satisfy the reporting person's tax liability in connection with the vesting of restricted stock units.

Read SEC document
March 06, 2020 Filed Apr 13, 2020 19:22 UTC Livongo Health, Inc. LVGO · Entity 145566 GiftCommon Stock 4,190 $0.00 $0.00
Disclosure

SEC source: 0000899243-20-010679 · doc4.xml · nonDerivative · entry 2

SHAPIRO LEE · CIK 0001213350 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,848,330

Read SEC document
March 05, 2020 Filed Mar 9, 2020 18:08 UTC Livongo Health, Inc. LVGO · Entity 145566 SaleCommon Stock 13,347 $27.94 $372,977.91
Disclosure

SEC source: 0001209191-20-017444 · doc4.xml · nonDerivative · entry 3

SHAPIRO LEE · CIK 0001213350 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,854,222

F1 · kind: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 12, 2019.

F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $27.80 to $28.04, inclusive.

Read SEC document
March 05, 2020 Filed Mar 9, 2020 18:08 UTC Livongo Health, Inc. LVGO · Entity 145566 SaleCommon Stock 12,606 $27.52 $346,978.89
Disclosure

SEC source: 0001209191-20-017444 · doc4.xml · nonDerivative · entry 2

SHAPIRO LEE · CIK 0001213350 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,867,569

F1 · kind: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 12, 2019.

F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $26.80 to $27.79, inclusive.

Read SEC document
March 05, 2020 Filed Mar 9, 2020 18:08 UTC Livongo Health, Inc. LVGO · Entity 145566 SaleCommon Stock 1,547 $26.36 $40,775.36
Disclosure

SEC source: 0001209191-20-017444 · doc4.xml · nonDerivative · entry 1

SHAPIRO LEE · CIK 0001213350 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,880,175

F1 · kind: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 12, 2019.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $25.72 to $26.64, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (3) and (4) to this Form 4.

Read SEC document
February 28, 2020 Filed Feb 28, 2020 16:30 UTC TIVITY HEALTH, INC. TVTY · Entity 125776 PurchaseCommon Stock 4,065 $12.00 $48,780.00
Disclosure

SEC source: 0001567619-20-005132 · doc1.xml · nonDerivative · entry 1

SHAPIRO LEE · CIK 0001213350 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 40,304

Read SEC document
February 20, 2020 Filed Apr 13, 2020 19:22 UTC Livongo Health, Inc. LVGO · Entity 145566 GiftCommon Stock 380 $0.00 $0.00
Disclosure

SEC source: 0000899243-20-010679 · doc4.xml · nonDerivative · entry 1

SHAPIRO LEE · CIK 0001213350 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,852,520

Read SEC document
February 18, 2020 Filed Feb 19, 2020 17:30 UTC Livongo Health, Inc. LVGO · Entity 145566 Tax withholdingCommon Stock 818 $26.93 $22,028.74
Disclosure

SEC source: 0001209191-20-010723 · doc4.xml · nonDerivative · entry 1

SHAPIRO LEE · CIK 0001213350 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,881,722

F1 · kind: The reported shares were withheld to satisfy the reporting person's tax liability in connection with the vesting of restricted stock units.

Read SEC document
January 21, 2020 Filed Jan 23, 2020 20:51 UTC Livongo Health, Inc. LVGO · Entity 145566 Tax withholdingCommon Stock 102,325 $28.90 $2,957,192.50
Disclosure

SEC source: 0001209191-20-004764 · doc4.xml · nonDerivative · entry 1

SHAPIRO LEE · CIK 0001213350 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,882,540

F1 · kind: The reported shares were withheld to satisfy the reporting person's tax liability in connection with the vesting of restricted stock units, or RSUs.

F1 · shares: The reported shares were withheld to satisfy the reporting person's tax liability in connection with the vesting of restricted stock units, or RSUs.

Read SEC document
October 28, 2019 Filed Oct 28, 2019 16:33 UTC Medidata Solutions, Inc. MDSO · Entity 154211 Disposition to issuerStock Option (right to buy) · Derivative 5,214 Not disclosed Strike: $13.98 Not disclosed
Disclosure

SEC source: 0001453814-19-000149 · wf-form4_157229477150358.xml · derivative · entry 3

SHAPIRO LEE · CIK 0001213350 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 5,214 shares

Expires 2022-05-16

F3 · shares: Pursuant to the Merger Agreement and by virtue of the Merger, each option to purchase Issuer Common Stock will be cancelled and converted into the right to receive an amount in cash (without interest and subject to deduction for any required withholding tax) equal to the product of (1) the total number of shares of Issuer Common Stock then covered by such option multiplied by (2) the excess, if any, of $92.25 per share over the exercise price per share under such option.

F3 · price: Pursuant to the Merger Agreement and by virtue of the Merger, each option to purchase Issuer Common Stock will be cancelled and converted into the right to receive an amount in cash (without interest and subject to deduction for any required withholding tax) equal to the product of (1) the total number of shares of Issuer Common Stock then covered by such option multiplied by (2) the excess, if any, of $92.25 per share over the exercise price per share under such option.

F4 · derivative.exercise_date: These options are fully vested and exercisable.

Read SEC document
October 28, 2019 Filed Oct 28, 2019 16:33 UTC Medidata Solutions, Inc. MDSO · Entity 154211 Disposition to issuerStock Option (right to buy) · Derivative 4,494 Not disclosed Strike: $11.50 Not disclosed
Disclosure

SEC source: 0001453814-19-000149 · wf-form4_157229477150358.xml · derivative · entry 2

SHAPIRO LEE · CIK 0001213350 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 4,494 shares

Expires 2021-05-31

F3 · shares: Pursuant to the Merger Agreement and by virtue of the Merger, each option to purchase Issuer Common Stock will be cancelled and converted into the right to receive an amount in cash (without interest and subject to deduction for any required withholding tax) equal to the product of (1) the total number of shares of Issuer Common Stock then covered by such option multiplied by (2) the excess, if any, of $92.25 per share over the exercise price per share under such option.

F3 · price: Pursuant to the Merger Agreement and by virtue of the Merger, each option to purchase Issuer Common Stock will be cancelled and converted into the right to receive an amount in cash (without interest and subject to deduction for any required withholding tax) equal to the product of (1) the total number of shares of Issuer Common Stock then covered by such option multiplied by (2) the excess, if any, of $92.25 per share over the exercise price per share under such option.

F4 · derivative.exercise_date: These options are fully vested and exercisable.

F3 · derivative.underlying_shares: Pursuant to the Merger Agreement and by virtue of the Merger, each option to purchase Issuer Common Stock will be cancelled and converted into the right to receive an amount in cash (without interest and subject to deduction for any required withholding tax) equal to the product of (1) the total number of shares of Issuer Common Stock then covered by such option multiplied by (2) the excess, if any, of $92.25 per share over the exercise price per share under such option.

Read SEC document
October 28, 2019 Filed Oct 28, 2019 16:33 UTC Medidata Solutions, Inc. MDSO · Entity 154211 Disposition to issuerCommon Stock 28,827 $92.25 $2,659,290.75
Disclosure

SEC source: 0001453814-19-000149 · wf-form4_157229477150358.xml · nonDerivative · entry 1

SHAPIRO LEE · CIK 0001213350 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

F1 · date: On October 28, 2019, pursuant to the Agreement and Plan of Merger, dated as of June 11, 2019, by and among Dassault Systemes SE ("DS"), Dassault Systemes Americas Corp., a Delaware corporation ("Parent"), 3DS Acquisition 6 Corp., a Delaware corporation and a wholly-owned subsidiary of Parent ("Merger Sub"), and Medidata Solutions, Inc., a Delaware corporation (the "Issuer"), Merger Sub merged with and into the Issuer, with the Issuer surviving as a wholly-owned subsidiary of Parent and an indirect wholly-owned subsidiary of DS (the "Merger").

F2 · shares: Disposed of pursuant to the Merger Agreement and by virtue of the Merger, in which each share of Medidata common stock, par value $0.01 per share ("Issuer Common Stock"), issued and outstanding immediately prior to the completion of the Merger (other than restricted share awards held by continuing employees) was converted into the right to receive $92.25 in cash and without interest (the "Merger Consideration").

F2 · price: Disposed of pursuant to the Merger Agreement and by virtue of the Merger, in which each share of Medidata common stock, par value $0.01 per share ("Issuer Common Stock"), issued and outstanding immediately prior to the completion of the Merger (other than restricted share awards held by continuing employees) was converted into the right to receive $92.25 in cash and without interest (the "Merger Consideration").

Read SEC document
July 29, 2019 Filed Jul 30, 2019 16:32 UTC Livongo Health, Inc. LVGO · Entity 145566 ConversionSeries E Convertible Preferred Stock · Derivative 60,000 Not disclosed Not disclosed
Disclosure

SEC source: 0000899243-19-020582 · doc4.xml · derivative · entry 15

SHAPIRO LEE · CIK 0001213350 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote.

Disclosed balance after: 0

Underlying: Common Stock · 60,000 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F7 · derivative.exercise_price: Each share of Series E Convertible Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the closing of the Issuer's initial public offering of Common Stock and had no expiration date.

F7 · price: Each share of Series E Convertible Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the closing of the Issuer's initial public offering of Common Stock and had no expiration date.

F7 · derivative.exercise_date: Each share of Series E Convertible Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the closing of the Issuer's initial public offering of Common Stock and had no expiration date.

F7 · derivative.expiration_date: Each share of Series E Convertible Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the closing of the Issuer's initial public offering of Common Stock and had no expiration date.

F9 · ownership.nature: The shares are held of record by 7Wire Ventures Wanxiang Strategic Fund I, LLC, or 7Wire Wanxiang. The reporting person serves as a Manager of 7Wire Management, the Manager of 7Wire Wanxiang. The reporting person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of the securities for purposes of Section 16 or for any other purpose.

Read SEC document
July 29, 2019 Filed Jul 30, 2019 16:32 UTC Livongo Health, Inc. LVGO · Entity 145566 ConversionSeries E Convertible Preferred Stock · Derivative 400,528 Not disclosed Not disclosed
Disclosure

SEC source: 0000899243-19-020582 · doc4.xml · derivative · entry 14

SHAPIRO LEE · CIK 0001213350 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote.

Disclosed balance after: 0

Underlying: Common Stock · 400,528 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F7 · derivative.exercise_price: Each share of Series E Convertible Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the closing of the Issuer's initial public offering of Common Stock and had no expiration date.

F7 · price: Each share of Series E Convertible Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the closing of the Issuer's initial public offering of Common Stock and had no expiration date.

F7 · derivative.exercise_date: Each share of Series E Convertible Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the closing of the Issuer's initial public offering of Common Stock and had no expiration date.

F7 · derivative.expiration_date: Each share of Series E Convertible Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the closing of the Issuer's initial public offering of Common Stock and had no expiration date.

F8 · ownership.nature: The shares are held of record by 7Wire Ventures LLC - Series Livongo E. The reporting person serves as a Manager of 7Wire Management, the Manager of 7Wire Ventures LLC - Series Livongo E. The reporting person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of the securities for purposes of Section 16 or for any other purpose.

Read SEC document
July 29, 2019 Filed Jul 30, 2019 16:32 UTC Livongo Health, Inc. LVGO · Entity 145566 ConversionSeries E Convertible Preferred Stock · Derivative 488,683 Not disclosed Not disclosed
Disclosure

SEC source: 0000899243-19-020582 · doc4.xml · derivative · entry 13

SHAPIRO LEE · CIK 0001213350 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote.

Disclosed balance after: 0

Underlying: Common Stock · 488,683 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F7 · derivative.exercise_price: Each share of Series E Convertible Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the closing of the Issuer's initial public offering of Common Stock and had no expiration date.

F7 · price: Each share of Series E Convertible Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the closing of the Issuer's initial public offering of Common Stock and had no expiration date.

F7 · derivative.exercise_date: Each share of Series E Convertible Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the closing of the Issuer's initial public offering of Common Stock and had no expiration date.

F7 · derivative.expiration_date: Each share of Series E Convertible Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the closing of the Issuer's initial public offering of Common Stock and had no expiration date.

F2 · ownership.nature: The shares are held of record by 7Wire Ventures Fund, L.P., or 7Wire LP. The reporting person serves as a Manager of 7Wire Management, LLC, or 7Wire Management, the Manager of 7Wire LP. The reporting person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of the securities for purposes of Section 16 or for any other purpose.

Read SEC document
July 29, 2019 Filed Jul 30, 2019 16:32 UTC Livongo Health, Inc. LVGO · Entity 145566 ConversionSeries D Convertible Preferred Stock · Derivative 361,718 Not disclosed Not disclosed
Disclosure

SEC source: 0000899243-19-020582 · doc4.xml · derivative · entry 12

SHAPIRO LEE · CIK 0001213350 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote.

Disclosed balance after: 0

Underlying: Common Stock · 361,718 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F5 · derivative.exercise_price: Each share of Series D Convertible Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the closing of the Issuer's initial public offering of Common Stock and had no expiration date.

F5 · price: Each share of Series D Convertible Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the closing of the Issuer's initial public offering of Common Stock and had no expiration date.

F5 · derivative.exercise_date: Each share of Series D Convertible Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the closing of the Issuer's initial public offering of Common Stock and had no expiration date.

F5 · derivative.expiration_date: Each share of Series D Convertible Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the closing of the Issuer's initial public offering of Common Stock and had no expiration date.

F6 · ownership.nature: The shares are held of record by 7Wire Ventures LLC - Series Livongo D. The reporting person serves as a Manager of 7Wire Management, the Manager of 7Wire Ventures LLC - Series Livongo D. The reporting person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of the securities for purposes of Section 16 or for any other purpose.

Read SEC document
July 29, 2019 Filed Jul 30, 2019 16:32 UTC Livongo Health, Inc. LVGO · Entity 145566 ConversionSeries D Convertible Preferred Stock · Derivative 250,800 Not disclosed Not disclosed
Disclosure

SEC source: 0000899243-19-020582 · doc4.xml · derivative · entry 11

SHAPIRO LEE · CIK 0001213350 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote.

Disclosed balance after: 0

Underlying: Common Stock · 250,800 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F5 · derivative.exercise_price: Each share of Series D Convertible Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the closing of the Issuer's initial public offering of Common Stock and had no expiration date.

F5 · price: Each share of Series D Convertible Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the closing of the Issuer's initial public offering of Common Stock and had no expiration date.

F5 · derivative.exercise_date: Each share of Series D Convertible Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the closing of the Issuer's initial public offering of Common Stock and had no expiration date.

F5 · derivative.expiration_date: Each share of Series D Convertible Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the closing of the Issuer's initial public offering of Common Stock and had no expiration date.

F2 · ownership.nature: The shares are held of record by 7Wire Ventures Fund, L.P., or 7Wire LP. The reporting person serves as a Manager of 7Wire Management, LLC, or 7Wire Management, the Manager of 7Wire LP. The reporting person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of the securities for purposes of Section 16 or for any other purpose.

Read SEC document
July 29, 2019 Filed Jul 30, 2019 16:32 UTC Livongo Health, Inc. LVGO · Entity 145566 ConversionSeries C Convertible Preferred Stock · Derivative 285,131 Not disclosed Not disclosed
Disclosure

SEC source: 0000899243-19-020582 · doc4.xml · derivative · entry 10

SHAPIRO LEE · CIK 0001213350 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote.

Disclosed balance after: 0

Underlying: Common Stock · 285,131 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_price: Each share of Series C Convertible Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the closing of the Issuer's initial public offering of Common Stock and had no expiration date.

F3 · price: Each share of Series C Convertible Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the closing of the Issuer's initial public offering of Common Stock and had no expiration date.

F3 · derivative.exercise_date: Each share of Series C Convertible Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the closing of the Issuer's initial public offering of Common Stock and had no expiration date.

F3 · derivative.expiration_date: Each share of Series C Convertible Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the closing of the Issuer's initial public offering of Common Stock and had no expiration date.

F4 · ownership.nature: The shares are held of record by 7Wire Ventures LLC - Series Livongo C. The reporting person serves as a Manager of 7Wire Management, the Manager of 7Wire Ventures LLC - Series Livongo C. The reporting person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of the securities for purposes of Section 16 or for any other purpose.

Read SEC document
July 29, 2019 Filed Jul 30, 2019 16:32 UTC Livongo Health, Inc. LVGO · Entity 145566 ConversionSeries C Convertible Preferred Stock · Derivative 2,104 Not disclosed Not disclosed
Disclosure

SEC source: 0000899243-19-020582 · doc4.xml · derivative · entry 9

SHAPIRO LEE · CIK 0001213350 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote.

Disclosed balance after: 0

Underlying: Common Stock · 2,104 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_price: Each share of Series C Convertible Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the closing of the Issuer's initial public offering of Common Stock and had no expiration date.

F3 · price: Each share of Series C Convertible Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the closing of the Issuer's initial public offering of Common Stock and had no expiration date.

F3 · derivative.exercise_date: Each share of Series C Convertible Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the closing of the Issuer's initial public offering of Common Stock and had no expiration date.

F3 · derivative.expiration_date: Each share of Series C Convertible Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the closing of the Issuer's initial public offering of Common Stock and had no expiration date.

F2 · ownership.nature: The shares are held of record by 7Wire Ventures Fund, L.P., or 7Wire LP. The reporting person serves as a Manager of 7Wire Management, LLC, or 7Wire Management, the Manager of 7Wire LP. The reporting person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of the securities for purposes of Section 16 or for any other purpose.

Read SEC document
July 29, 2019 Filed Jul 30, 2019 16:32 UTC Livongo Health, Inc. LVGO · Entity 145566 ConversionSeries A Convertible Preferred Stock · Derivative 3,506 Not disclosed Not disclosed
Disclosure

SEC source: 0000899243-19-020582 · doc4.xml · derivative · entry 8

SHAPIRO LEE · CIK 0001213350 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote.

Disclosed balance after: 0

Underlying: Common Stock · 3,506 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each share of Series A Convertible Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the closing of the Issuer's initial public offering of Common Stock and had no expiration date.

F1 · price: Each share of Series A Convertible Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the closing of the Issuer's initial public offering of Common Stock and had no expiration date.

F1 · derivative.exercise_date: Each share of Series A Convertible Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the closing of the Issuer's initial public offering of Common Stock and had no expiration date.

F1 · derivative.expiration_date: Each share of Series A Convertible Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the closing of the Issuer's initial public offering of Common Stock and had no expiration date.

F2 · ownership.nature: The shares are held of record by 7Wire Ventures Fund, L.P., or 7Wire LP. The reporting person serves as a Manager of 7Wire Management, LLC, or 7Wire Management, the Manager of 7Wire LP. The reporting person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of the securities for purposes of Section 16 or for any other purpose.

Read SEC document
July 29, 2019 Filed Jul 30, 2019 16:32 UTC Livongo Health, Inc. LVGO · Entity 145566 ConversionCommon Stock 60,000 Not disclosed Not disclosed
Disclosure

SEC source: 0000899243-19-020582 · doc4.xml · nonDerivative · entry 5

SHAPIRO LEE · CIK 0001213350 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote.

Disclosed balance after: 60,000

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F7 · price: Each share of Series E Convertible Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the closing of the Issuer's initial public offering of Common Stock and had no expiration date.

F9 · ownership.nature: The shares are held of record by 7Wire Ventures Wanxiang Strategic Fund I, LLC, or 7Wire Wanxiang. The reporting person serves as a Manager of 7Wire Management, the Manager of 7Wire Wanxiang. The reporting person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of the securities for purposes of Section 16 or for any other purpose.

Read SEC document
July 29, 2019 Filed Jul 30, 2019 16:32 UTC Livongo Health, Inc. LVGO · Entity 145566 ConversionCommon Stock 400,528 Not disclosed Not disclosed
Disclosure

SEC source: 0000899243-19-020582 · doc4.xml · nonDerivative · entry 4

SHAPIRO LEE · CIK 0001213350 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote.

Disclosed balance after: 400,528

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F7 · price: Each share of Series E Convertible Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the closing of the Issuer's initial public offering of Common Stock and had no expiration date.

F8 · ownership.nature: The shares are held of record by 7Wire Ventures LLC - Series Livongo E. The reporting person serves as a Manager of 7Wire Management, the Manager of 7Wire Ventures LLC - Series Livongo E. The reporting person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of the securities for purposes of Section 16 or for any other purpose.

Read SEC document
July 29, 2019 Filed Jul 30, 2019 16:32 UTC Livongo Health, Inc. LVGO · Entity 145566 ConversionCommon Stock 361,718 Not disclosed Not disclosed
Disclosure

SEC source: 0000899243-19-020582 · doc4.xml · nonDerivative · entry 3

SHAPIRO LEE · CIK 0001213350 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote.

Disclosed balance after: 361,718

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F5 · price: Each share of Series D Convertible Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the closing of the Issuer's initial public offering of Common Stock and had no expiration date.

F6 · ownership.nature: The shares are held of record by 7Wire Ventures LLC - Series Livongo D. The reporting person serves as a Manager of 7Wire Management, the Manager of 7Wire Ventures LLC - Series Livongo D. The reporting person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of the securities for purposes of Section 16 or for any other purpose.

Read SEC document
July 29, 2019 Filed Jul 30, 2019 16:32 UTC Livongo Health, Inc. LVGO · Entity 145566 ConversionCommon Stock 285,131 Not disclosed Not disclosed
Disclosure

SEC source: 0000899243-19-020582 · doc4.xml · nonDerivative · entry 2

SHAPIRO LEE · CIK 0001213350 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote.

Disclosed balance after: 285,131

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · price: Each share of Series C Convertible Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the closing of the Issuer's initial public offering of Common Stock and had no expiration date.

F4 · ownership.nature: The shares are held of record by 7Wire Ventures LLC - Series Livongo C. The reporting person serves as a Manager of 7Wire Management, the Manager of 7Wire Ventures LLC - Series Livongo C. The reporting person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of the securities for purposes of Section 16 or for any other purpose.

Read SEC document
July 29, 2019 Filed Jul 30, 2019 16:32 UTC Livongo Health, Inc. LVGO · Entity 145566 ConversionCommon Stock 745,093 Not disclosed Not disclosed
Disclosure

SEC source: 0000899243-19-020582 · doc4.xml · nonDerivative · entry 1

SHAPIRO LEE · CIK 0001213350 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote.

Disclosed balance after: 1,159,901

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each share of Series A Convertible Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the closing of the Issuer's initial public offering of Common Stock and had no expiration date.

F3 · price: Each share of Series C Convertible Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the closing of the Issuer's initial public offering of Common Stock and had no expiration date.

F5 · price: Each share of Series D Convertible Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the closing of the Issuer's initial public offering of Common Stock and had no expiration date.

F7 · price: Each share of Series E Convertible Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the closing of the Issuer's initial public offering of Common Stock and had no expiration date.

F2 · ownership.nature: The shares are held of record by 7Wire Ventures Fund, L.P., or 7Wire LP. The reporting person serves as a Manager of 7Wire Management, LLC, or 7Wire Management, the Manager of 7Wire LP. The reporting person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of the securities for purposes of Section 16 or for any other purpose.

Read SEC document
May 29, 2019 Filed May 30, 2019 16:55 UTC Medidata Solutions, Inc. MDSO · Entity 154211 GrantCommon Stock 2,799 $0.00 $0.00
Disclosure

SEC source: 0001453814-19-000089 · wf-form4_155924972328476.xml · nonDerivative · entry 1

SHAPIRO LEE · CIK 0001213350 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 28,827

F1 · shares: Represents shares of restricted stock. The restrictions will lapse in full on May 29, 2020.

F2 · price: Granted as compensation for services.

Read SEC document
May 23, 2019 Filed May 28, 2019 15:07 UTC TIVITY HEALTH, INC. TVTY · Entity 125776 GrantCommon Stock 6,098 $0.00 $0.00
Disclosure

SEC source: 0001567619-19-012201 · doc1.xml · nonDerivative · entry 1

SHAPIRO LEE · CIK 0001213350 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 36,239

F1 · shares: Reflects restricted stock units that vest on the earlier of (i) the first anniversary of the Grant Date (such Grant Date being 5/23/2019), or (ii) the first annual meeting of the stockholders of Tivity Health that occurs after the Grant Date.

Read SEC document
March 20, 2019 Filed Mar 22, 2019 15:00 UTC TIVITY HEALTH, INC. TVTY · Entity 125776 PurchaseCommon Stock 4,050 $17.80 $72,090.00
Disclosure

SEC source: 0001567619-19-007451 · doc1.xml · nonDerivative · entry 1

SHAPIRO LEE · CIK 0001213350 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 30,141

Read SEC document
July 26, 2018 Filed Jul 26, 2018 17:13 UTC Medidata Solutions, Inc. MDSO · Entity 154211 SaleCommon Stock 12,500 $76.16 $952,000.00
Disclosure

SEC source: 0001453814-18-000108 · wf-form4_153263957212902.xml · nonDerivative · entry 1

SHAPIRO LEE · CIK 0001213350 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 26,028

F1 · shares: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 14, 2018.

F2 · price: Such transaction was executed in multiple trades at prices ranging from $75.39 to $77.32. The price reported reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

Read SEC document
May 30, 2018 Filed May 31, 2018 16:24 UTC Medidata Solutions, Inc. MDSO · Entity 154211 GrantCommon Stock 3,025 $0.00 $0.00
Disclosure

SEC source: 0001453814-18-000088 · wf-form4_152779828058021.xml · nonDerivative · entry 2

SHAPIRO LEE · CIK 0001213350 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 38,528

F2 · shares: Represents shares of restricted stock. The restrictions will lapse in full on May 30, 2019.

F3 · price: Granted as compensation for services.

Read SEC document
May 24, 2018 Filed May 25, 2018 13:05 UTC TIVITY HEALTH, INC. TVTY · Entity 125776 GrantCommon Stock 2,876 $0.00 $0.00
Disclosure

SEC source: 0001140361-18-025695 · doc1.xml · nonDerivative · entry 1

SHAPIRO LEE · CIK 0001213350 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 26,091

F1 · shares: Reflects restricted stock units that vest on the earlier of (i) the first anniversary of the Grant Date (such Grant Date being 5/24/2018), or (ii) the first annual meeting of the stockholders of Tivity Health that occurs after the Grant Date.

Read SEC document
March 05, 2018 Filed May 31, 2018 16:24 UTC Medidata Solutions, Inc. MDSO · Entity 154211 GiftCommon Stock 375 $0.00 $0.00
Disclosure

SEC source: 0001453814-18-000088 · wf-form4_152779828058021.xml · nonDerivative · entry 1

SHAPIRO LEE · CIK 0001213350 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 35,467

F1 · price: Bona fide gift by the Reporting Person for no consideration.

Read SEC document
November 28, 2017 Filed Feb 13, 2018 16:46 UTC Medidata Solutions, Inc. MDSO · Entity 154211 GiftCommon Stock 59 $0.00 $0.00
Disclosure

SEC source: 0001453814-18-000006 · wf-form5_151855832283551.xml · nonDerivative · entry 2

SHAPIRO LEE · CIK 0001213350 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 35,842

F1 · price: Bona fide gift by the Reporting Person for no consideration.

Read SEC document
November 27, 2017 Filed Feb 13, 2018 16:46 UTC Medidata Solutions, Inc. MDSO · Entity 154211 GiftCommon Stock 364 $0.00 $0.00
Disclosure

SEC source: 0001453814-18-000006 · wf-form5_151855832283551.xml · nonDerivative · entry 1

SHAPIRO LEE · CIK 0001213350 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 35,901

F1 · price: Bona fide gift by the Reporting Person for no consideration.

Read SEC document
May 30, 2017 Filed Jun 1, 2017 16:44 UTC Medidata Solutions, Inc. MDSO · Entity 154211 GrantCommon Stock 3,334 $0.00 $0.00
Disclosure

SEC source: 0001453814-17-000091 · wf-form4_149634984881074.xml · nonDerivative · entry 2

SHAPIRO LEE · CIK 0001213350 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 36,265

F2 · shares: Represents shares of restricted stock. The restrictions will lapse in full on May 30, 2018.

F3 · price: Granted as compensation for services.

Read SEC document
May 25, 2017 Filed May 30, 2017 10:56 UTC TIVITY HEALTH, INC. TVTY · Entity 125776 GrantCommon Stock 3,012 $0.00 $0.00
Disclosure

SEC source: 0001140361-17-022650 · doc1.xml · nonDerivative · entry 1

SHAPIRO LEE · CIK 0001213350 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 23,215

F1 · shares: Reflects restricted stock units that vest on 5/25/2018.

Read SEC document
February 14, 2017 Filed Jun 1, 2017 16:44 UTC Medidata Solutions, Inc. MDSO · Entity 154211 GiftCommon Stock 644 $0.00 $0.00
Disclosure

SEC source: 0001453814-17-000091 · wf-form4_149634984881074.xml · nonDerivative · entry 1

SHAPIRO LEE · CIK 0001213350 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 32,931

F1 · price: Bona fide gift by the Reporting Person for no consideration.

Read SEC document
December 16, 2016 Filed Feb 14, 2017 17:41 UTC Medidata Solutions, Inc. MDSO · Entity 154211 GiftCommon Stock 742 $0.00 $0.00
Disclosure

SEC source: 0001453814-17-000008 · wf-form5_148711202004438.xml · nonDerivative · entry 2

SHAPIRO LEE · CIK 0001213350 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 33,575

F1 · price: Bona fide gift by the Reporting Person for no consideration.

Read SEC document
December 15, 2016 Filed Feb 14, 2017 17:41 UTC Medidata Solutions, Inc. MDSO · Entity 154211 GiftCommon Stock 992 $0.00 $0.00
Disclosure

SEC source: 0001453814-17-000008 · wf-form5_148711202004438.xml · nonDerivative · entry 1

SHAPIRO LEE · CIK 0001213350 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 34,317

F1 · price: Bona fide gift by the Reporting Person for no consideration.

Read SEC document
November 04, 2016 Filed Nov 7, 2016 14:00 UTC TIVITY HEALTH, INC. HWAY · Entity 125776 PurchaseCommon Stock 1,266 $19.53 $24,724.98
Disclosure

SEC source: 0001140361-16-085028 · doc1.xml · nonDerivative · entry 1

SHAPIRO LEE · CIK 0001213350 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 20,203

F1 · price: This transaction was executed in multiple trades at prices ranging from $19.50 to $19.55. The price reported above reflects the weighted-average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected.

Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.